Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

BACKGROUND: Prospectively designed studies assessing the exposure‐response profile of vedolizumab are lacking. Observational exposure‐response data for vedolizumab are limited and have not been adjusted for potential confounding factors, particularly those that may affect vedolizumab clearance. AIMS...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Aliment Pharmacol Ther
Hlavní autoři: Osterman, Mark T., Rosario, Maria, Lasch, Karen, Barocas, Morris, Wilbur, Jayson D., Dirks, Nathanael L., Gastonguay, Marc R.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Dose Optimisation of Vedolizumab in Ulcerative Colitis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590294/
https://ncbi.nlm.nih.gov/pubmed/30663076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15113
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky